Qiagen NV (NYSE:QGEN) was the recipient of a large drop in short interest in September. As of September 30th, there was short interest totalling 3,460,000 shares, a drop of 19.9% from the September 15th total of 4,320,000 shares. Approximately 1.5% of the shares of the stock are sold short. Based on an average daily volume of 1,470,000 shares, the short-interest ratio is currently 2.4 days.
QGEN has been the subject of several research analyst reports. Kepler Capital Markets raised Qiagen from a "hold" rating to a "buy" rating and set a $59.32 price objective for the company in a research note on Monday, September 28th. Warburg Research reaffirmed a "neutral" rating on shares of Qiagen in a research note on Tuesday, June 23rd. JPMorgan Chase & Co. reiterated an "overweight" rating and set a $60.00 target price on shares of Qiagen in a report on Thursday, August 20th. Exane BNP Paribas upgraded Qiagen from a "neutral" rating to an "outperform" rating in a report on Friday, August 14th. Finally, Berenberg Bank upgraded Qiagen from a "hold" rating to a "buy" rating in a report on Monday, August 17th. Nine equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. The company has an average rating of "Buy" and an average target price of $50.72.
A number of large investors have recently added to or reduced their stakes in the business. NuWave Investment Management LLC purchased a new stake in shares of Qiagen during the second quarter worth about $36,000. Mitsubishi UFJ Trust & Banking Corp purchased a new stake in shares of Qiagen during the second quarter worth about $73,000. CSat Investment Advisory L.P. increased its position in shares of Qiagen by 377.1% during the second quarter. CSat Investment Advisory L.P. now owns 3,674 shares of the company's stock worth $157,000 after acquiring an additional 2,904 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Qiagen during the third quarter worth about $214,000. Finally, Diversified Trust Co purchased a new stake in shares of Qiagen during the third quarter worth about $221,000. 61.81% of the stock is currently owned by institutional investors.
Shares of QGEN traded down $0.22 during trading hours on Friday, hitting $52.32. The stock had a trading volume of 1,036,447 shares, compared to its average volume of 1,767,927. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.50 and a current ratio of 1.71. The firm has a market cap of $11.92 billion, a P/E ratio of 1,744.00, a P/E/G ratio of 1.07 and a beta of 0.32. The company's fifty day simple moving average is $51.10 and its 200 day simple moving average is $46.03. Qiagen has a 12-month low of $27.76 and a 12-month high of $55.27.
Qiagen (NYSE:QGEN) last issued its earnings results on Tuesday, August 4th. The company reported $0.55 earnings per share for the quarter, hitting the consensus estimate of $0.55. Qiagen had a return on equity of 15.85% and a net margin of 0.86%. The business had revenue of $443.30 million for the quarter, compared to analyst estimates of $441.80 million. During the same period last year, the company posted $0.34 EPS. The business's quarterly revenue was up 16.2% on a year-over-year basis. As a group, sell-side analysts predict that Qiagen will post 2.08 earnings per share for the current fiscal year.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Further Reading: What Are Treasury Bonds?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Technology Stocks that Analysts Love
There are more than 1,100 technology companies traded on public markets in the United States. Given the sheer number of hardware makers, social networks, software companies, service providers and other tech stocks, it can be hard to identify which tech companies are going to outperform the market.
Fortunately, Wall Street's brightest minds have already done this for us. Every year, analyst issue approximately 15,000 distinct recommendations for technology companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same tech stock.
This slide show lists the 15 technology companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.
View the "15 Technology Stocks that Analysts Love".